Tradestie Institutional Equity Comparison Engine

ICCC vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ICCC Overall Edge

ICCC Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while SRZN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ICCC
ICCC N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner ICCC
Op Margin 15.2% vs -485.4% ยท YoY +11.5% vs +408.6%
Momentum & Technical Winner SRZN
1Y +88.8% vs +166.7% ยท 52W Pos 91% vs 79%
Options & Structure Winner SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (5th %ile IV)
ICCC NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
1M Return +6.23%
1Y Return +88.76%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap $602.5M
1M Return +37.88%
1Y Return +166.67%
Forward P/E N/M
Unified AI Score
34.3 / 100 SELL
Tech 5.0 Fund 32.0 Flow 65.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ICCC +88.76% SRZN +166.67% Spread: +77.91 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ICCC Revenue SRZN Revenue ICCC Op. Margin SRZN Op. Margin Margin Edge
FY2018 $10M N/A -13.2% N/A ICCC
FY2019 $10M N/A -7.0% N/A ICCC
FY2020 $20M N/A -9.0% N/A ICCC
FY2021 $20M N/A 1.3% N/A ICCC
FY2022 $20M $10M -12.4% -354.7% ICCC
FY2023 $20M N/A -32.9% N/A ICCC
FY2024 $30M $10M -6.2% -239.7% ICCC
FY2025 $30M $0M 6.0% -1210.6% ICCC

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ICCC (7) vs SRZN (2)
Institutional Metric ICCC SRZN Criterion Row Winner
Market Capitalization Scale $97.7M $602.5M Larger Scale SRZN
Trailing P/E Ratio Valuation 56.6x N/M Lower Multiple ICCC
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +11.5% +408.6% Higher Growth SRZN
Operating Margin (TTM) Profitability 15.2% -485.4% Higher Margin ICCC
Net Profit Margin Profitability 2.6% 0.0% Higher Margin ICCC
Return on Equity (ROE) Capital Efficiency 2.6% -62.8% Higher ROE ICCC
52-Week Range Position Momentum 91% ($5โ€“$12) 79% ($12โ€“$38) Stronger Trend ICCC
Beta / 30D Volatility Risk Regime 0.24ฮฒ ยท 46% Vol 1.21ฮฒ ยท 62% Vol Lower Realized Risk ICCC
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 34.3 / 100 (SELL) Higher Composite ICCC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ICCC vs SRZN Buy Guide
ICCC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ICCC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
37d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ICCC nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.